United States v. Cintrón-Echautegui

604 F.3d 1, 2010 U.S. App. LEXIS 7646, 2010 WL 1463240
CourtCourt of Appeals for the First Circuit
DecidedApril 14, 2010
Docket08-1800
StatusPublished
Cited by116 cases

This text of 604 F.3d 1 (United States v. Cintrón-Echautegui) is published on Counsel Stack Legal Research, covering Court of Appeals for the First Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Cintrón-Echautegui, 604 F.3d 1, 2010 U.S. App. LEXIS 7646, 2010 WL 1463240 (1st Cir. 2010).

Opinion

SELYA, Circuit Judge.

Defendant-appellant José Cintrón-Echautegui, who pleaded guilty to a charge of conspiracy to distribute controlled substances, alleges that the district court erred in calculating drug quantity and, therefore, imposed an overly harsh sentence. Discerning no error, we affirm the judgment below.

Because this appeal follows a guilty plea, we draw the facts from the change-of-plea colloquy, the presentence investigation report (PSI Report), and the transcript of the disposition hearing. See United States v. Santos, 357 F.3d 136, 138 (1st Cir.2004); United States v. Dietz, 950 F.2d 50, 51 (1st Cir.1991).

A federal grand jury sitting in the District of Puerto Rico indicted a number of suspected participants in a notorious drug ring known as “Las Avispas.” These individuals, including the appellant, were charged with conspiring to distribute controlled substances. See 21 U.S.C. §§ 841(a)(1), 846.

*3 The appellant initially maintained his innocence. Along with several codefendants, he went to trial on February 11, 2008. After five days, however, he opted out of the trial and entered a straight guilty plea, unaccompanied by any plea agreement. Meanwhile, the trial continued as to six of his codefendants, all of whom were eventually found guilty.

During his change-of-plea hearing, the prosecutor maintained that the appellant had sold drugs for Las Avispas during a four-year span from 2003 to 2007. The appellant accepted this account. In addition, he admitted to possessing 255 capsules of crack cocaine, which contained, in the aggregate, 17.53 grams of cocaine base.

In accordance with the customary routine, the district court directed the probation department to prepare the PSI Report. That report, when completed, was delivered to the prosecutor, the appellant (through his counsel), and the court. We summarize certain pertinent entries.

According to the PSI Report, Las Avis-pas purveyed an assortment of drugs, including crack cocaine (cocaine base), heroin, and marijuana. The report referenced trial testimony from a cooperating witness, José Rivera-Diaz, who confirmed that Las Avispas ran two drug points, each of which operated twenty-four hours a day, seven days a week, fifty-two weeks a year (with the exception of Holy Friday).

Each drug point was manned by three shifts of sellers daily — a morning shift, an afternoon shift, and a night shift. On average, each shift participant would sell approximately 200 capsules of crack cocaine, together with other kinds of drugs, during each morning and afternoon shift. The night shifts were busier; each night-shift vendor would sell, on average, between 700 and 900 capsules of crack, along with other drugs.

The PSI Report summarized the trial testimony of a forensic scientist. This portion of the report related that a typical crack cocaine capsule sold by Las Avispas contained, on average, .075 grams of cocaine base. Conservatively assuming average sales of 1,000 capsules per day, the drug ring had annual sales of 27.3 kilograms of cocaine base. Thus, during its four years of operations, the drug ring sold an estimated total of 109.2 kilograms of cocaine base.

The PSI Report further noted that, at trial, the scientist had been cross-examined about the methodology used to determine the per-capsule amount of cocaine base. The scientist responded that sampling was the method he had used, and that the samples used were capsules actually seized from the Las Avispas drug points. In the scientist’s opinion, this sampling permitted a reasoned determination of an average drug weight per capsule.

The PSI Report indicated, too, that a confidential informant (Cl) had identified the appellant as a seller of drugs for Las Avispas. The Cl stated that the appellant was “usually” at one of the drug points, “dealing drugs” with two other members of the ring (whom he named). Both of these men had been indicted alongside the appellant.

The PSI Report contained more information from the Cl about the appellant. For example, the Cl identified the appellant as having stored both guns and drugs for Las Avispas. Moreover, the Cl said that, on one occasion, the appellant had warned him (the Cl) that the police were en route to one of the drug points.

The PSI Report went into some detail anent possible sentencing options. Among other things, the probation department recommended a series of sentencing calculations premised on the November 2007 *4 edition of the guidelines (which controls here). It suggested a base offense level of 38, premised on a drug quantity of more than 4 .5 kilograms of cocaine base. See USSG § 2Dl.l(a)(5), (c)(1). It arrived at a total offense level of 40 after applying various enhancing and mitigating adjustments, none of which is controverted here. Placing the appellant in criminal history category I, the probation department envisioned a guideline sentencing range (GSR) of 292-365 months. See id. Ch. 5, Pt. A (sentencing table).

The appellant interposed a timely objection to the proposed drug quantity determination and, by fair implication, to the calculations employed therein. He argued that the PSI Report rested this determination on unreliable computations and, thus, exaggerated his role in the conspiracy. 1

The district court convened the disposition hearing on May 20, 2008. The appellant renewed his objection to the proposed drug quantity. The government endorsed it. The court concluded that the estimates for both the number of capsules sold and the per-capsule drug weight were accurate. Nevertheless, the court decided to use a set of related assumptions even “more favorable to the [appellant]”: it assumed that the appellant worked only daytime shifts; that he worked only three shifts a week; and that he sold an average of 200 capsules per shift.

Based on these assumptions, the court attributed 2.3 kilograms of cocaine base per year to the appellant. Taking into account the four-year life of the conspiracy, the court attributed a total drug quantity of 9.2 kilograms of crack to the appellant. 2 All of these findings were grounded in the recitals contained in the PSI Report.

With the drug quantity contretemps resolved, the court proceeded to sentence the appellant to a 292-month incarcerative term (the low end of the GSR). This timely appeal followed.

The appellant advances two principal claims of error. 3 First, he argues that the sentencing court failed to make an individualized finding of drug quantity. Second, he argues that, in all events, the drug quantity determination was not supported by competent evidence. We deal with these claims sequentially.

We begin with the nature of the sentencing court’s drug quantity determination.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Forteza-Garcia v. United States
130 F.4th 18 (First Circuit, 2025)
United States v. Salvador Gutierrez
128 F.4th 299 (First Circuit, 2025)
United States v. Tilley
105 F.4th 482 (First Circuit, 2024)
United States v. Dennison
73 F.4th 70 (First Circuit, 2023)
United States v. Ford
73 F.4th 57 (First Circuit, 2023)
United States v. Cardozo
68 F.4th 725 (First Circuit, 2023)
United States v. Fitzpatrick
67 F.4th 497 (First Circuit, 2023)
(HC) Donovan v. Diaz
E.D. California, 2023
United States v. Mejia
First Circuit, 2022
United States v. Rivera-Ruiz
43 F.4th 172 (First Circuit, 2022)
Porter v. Coyne-Fague
35 F.4th 68 (First Circuit, 2022)
United States v. Hernandez-Negron
21 F.4th 19 (First Circuit, 2021)
United States v. Ortiz-Vidot
First Circuit, 2021
United States v. Austin
991 F.3d 51 (First Circuit, 2021)
United States v. Davila-Bonilla
968 F.3d 1 (First Circuit, 2020)
United States v. Mendoza-Maisonet
962 F.3d 1 (First Circuit, 2020)
United States v. Diaz-Rivera
957 F.3d 20 (First Circuit, 2020)

Cite This Page — Counsel Stack

Bluebook (online)
604 F.3d 1, 2010 U.S. App. LEXIS 7646, 2010 WL 1463240, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-cintron-echautegui-ca1-2010.